Pediatric Vesicoureteral Reflux

Pediatric Vesicoureteral Reflux

No Results

No Results


Vesicoureteral reflux (VUR), or the retrograde flow of urine from the bladder into the ureter, is an anatomic and functional disorder that can result in substantial morbidity, both from acute infection and from the sequelae of reflux nephropathy.

Most children with VUR present in two distinct groups: those with hydronephrosis and those with clinical urinary tract infection (UTI). Hydronephrosis is often prenatally identified by means of ultrasonography. These children typically progress through evaluation and treatment in the absence of clinical illness.

Even for experienced pediatricians, the diagnosis of UTI in children can be difficult, for the following reasons:

A small group of children without evidence of UTI present with symptoms of sterile reflux, which can include flank or abdominal pain before or during voiding, as well as double voiding or incomplete emptying resulting from delayed drainage of urine out of the upper tracts.

As with the history, few findings on physical examination suggest VUR or UTI. Fever, flank or abdominal tenderness, or an enlarged palpable kidney may be present.

See Clinical Presentation for more detail.

Diagnosis of UTI depends on obtaining accurate urine culture findings. Although the white blood cell (WBC) count, serum levels of C-reactive protein (CRP), and other blood tests are often used to assist with the diagnosis, no laboratory tests can reliably distinguish cystitis from pyelonephritis. However, other laboratory tests have the following uses:

Imaging studies are the basis of diagnosis and management of VUR. The standard imaging tests include renal and bladder ultrasonography and voiding cystourethrography (VCUG). Indications for imaging studies are as follows:

Although the traditional approach in children with UTI has been evaluation for VUR with VCUG or radionuclide cystography (RNC), some authorities now advocate that children with a history of febrile UTI undergo a dimercaptosuccinic acid (DMSA) renal scan, to assess for evidence of kidney involvement, kidney scarring, or both; if DMSA scan findings are positive, VCUG is recommended.

One approach is to perform RNC as the initial screening test in girls and then to perform standard VCUG when VUR is observed. Other clinicians use VCUG for the initial diagnosis and use RNC for follow-up studies. The 2011 American Academy of Pediatrics (AAP) guidelines for management of UTI in children aged 2-24 months recommended that VCUG not be performed after an initial febrile UTI. [1]

Voiding cystourethrography

VCUG is the criterion standard in diagnosis of VUR, providing precise anatomic detail and allows grading of the reflux. The International Classification System for VUR is as follows [2] :

In general, VCUG should be performed after the child has fully recovered from the UTI. However, some children demonstrate reflux only during an episode of cystitis.

Radionuclide cystography

See Workup for more detail.

General principles of management in children with known VUR are as follows [3] :


Antibiotic prophylaxis

Antibiotics are used as follows:

The prophylactic regimen also includes regular follow-up care and imaging (eg, renal ultrasonography and VCUG or nuclear cystography every 12-18 months).

Children with dysfunctional elimination require aggressive bladder and bowel management. In toilet-trained children with recurrent UTI, voiding postponement behaviors, incomplete emptying, and constipation are extremely common and may be much more important etiologic factors than the reflux itself. Anticholinergic medication, in conjunction with timed voiding, may improve symptoms of dysfunctional voiding and reduces the risk of infection in select patients.

Surgical care

Accepted indications for surgical treatment include the following:

Virtually all open antireflux operations involve reconstruction of the ureterovesical junction to create a lengthened submucosal tunnel for the ureter, which functions as a one-way valve as the bladder fills. Dozens of procedures have been described. Options include open antireflux surgery via an extravesical or an intravesical approach and endoscopic antireflux treatment.

See Treatment and Medication for more detail.

Vesicoureteral reflux (VUR), or the retrograde flow of urine from the bladder into the ureter, is an anatomic and functional disorder with potentially serious consequences. It takles either of the following forms:

In both conditions, the ureterovesical junction (UVJ) fails to function as a one-way valve, giving lower urinary tract bacteria access to the normally sterile upper tracts. Although VUR has been recognized as an anatomic phenomenon for centuries, it was not until relatively recently that the substantial morbidity and mortality associated with the condition were recognized.

Early studies demonstrated a correlation between reflux and chronic pyelonephritis in paraplegic individuals and a correlation among urinary tract infection (UTI), reflux, and chronic pyelonephritis in children, which suggested that prevention of VUR may result in reduced prevalence of renal complications. The subsequent developments in the medical and surgical management of VUR formed the basis of the evolving field of pediatric urology.

The objectives in the current treatment of VUR are twofold, as follows:

Controversy persists over the optimal management of VUR, specifically with respect to the timing, technique, and benefits of surgical correction.

After entering the bladder through the muscular hiatus of the detrusor, the normal distal ureter passes through a submucosal tunnel before opening into the bladder lumen via the ureteral orifice. If the length of the submucosal tunnel or its muscular backing is inadequate, the valve mechanism is incompetent, resulting in reflux. Careful anatomic measurements suggest that the ratio of tunnel length to ureteral diameter must be at least 5:1 to prevent reflux. This fundamental observation is the basis for almost all surgical procedures to correct the disorder.

Beyond the fetal stage, anatomic reflux alone rarely produces renal damage. Experiments in pigs have demonstrated renal scarring in sterile refluxing systems; although the kidneys may display scarring, dysplasia, or both in some patients with antenatally identified and presumably sterile reflux, the data overwhelmingly implicate ascending infection and pyelonephritis as the essential causes of reflux nephropathy. Large studies have repeatedly demonstrated a close correlation between the frequency of UTI and the severity of reflux nephropathy in patients with VUR. [1, 5, 3]

Scarring may result from a single episode of pyelonephritis, especially in very young patients. Ransley and Risdon named this occurrence the “big bang” effect. [6] Most scarring tends to occur at the renal poles, where the anatomy of the renal papillae permits backflow of urine into the collecting ducts. This phenomenon is referred to as intrarenal reflux and gives pathogenic bacteria access to the renal tubules.

The subsequent cascade of inflammation, with release of superoxide and other mediators, results in local tissue ischemia and fibrosis. Over time, when enough renal parenchyma is affected, hypertension, renal insufficiency, and renal failure can result. The reason kidneys of children are so susceptible to damage is unclear; this may be due to reduced levels of renal superoxide dismutase in children.

The cause of the defect in primary reflux is unknown.

The existence of a strong genetic component is indicated by the high rate of reflux in relatives of patients with reflux, but the mechanism of transmission is not clear. Some investigators favor a polygenic mode of inheritance, whereas others have suggested autosomal or sex-linked transmission with variable penetrance.

The possibility that UTI may cause reflux has also been investigated. Indeed, a subset of patients has been identified in whom reflux was detectable only during an episode of cystitis. However, most authorities think that UTI and reflux are independent variables and that rates of VUR are higher in children with UTI because these children are actively screened for reflux. The cause-and-effect picture is even less clear in children with secondary reflux.

Rates of reflux are likely increased in the setting of congenital bladder outlet obstruction and neurogenic bladder. More than 50% of boys with posterior urethral valves have VUR. Similar results were seen in a series of children undergoing urodynamic studies for neurogenic bladder.

Dysfunctional voiding, with its inherent increase in intravesical pressure, likely also results in reflux, even in otherwise healthy children. Uninhibited bladder contractions, often associated with contraction of the voluntarily controlled external urinary sphincter to prevent wetting, increase intravesical pressure. The combination of high-pressure voiding and VUR increases the risk of pyelonephritis beyond that of the child with low-pressure reflux.

Confounding all of these data is the fact that urodynamic studies on children are difficult to perform and evaluate; this is true especially with infants, in whom normal reference data are sparse. Whether VUR observed in association with voiding dysfunction and obstruction is a direct result of that dysfunction or simply a component of a grossly abnormal urinary tract is not known.

A unique and complex group of children presents with dysfunctional elimination, which consists of a symptom complex heralded by infection, severe constipation, and daytime wetting. Despite the primary urinary tract presentation, the primary focus should be in the management of constipation and bowel habits. A subset of these children have infrequent voiding and incomplete bladder emptying, which further increases the likelihood of UTI.

The overall prevalence of VUR is unknown because many children are asymptomatic and the invasive testing required for diagnosis is performed only when clinically indicated. Several older reports of imaging studies performed on healthy children prior to oversight by institutional review boards demonstrated rates of 1-2%, but most of these studies were small and failed to clearly characterize their subject populations. The evidence is clear that the prevalence of VUR is higher among children with UTIs (15-70%, depending on age). Among infants antenatally identified with hydronephrosis on ultrasonography (US), approximately one third were postnatally found to have VUR.

The incidence of reflux clearly is influenced by genetic factors, though specific modes of inheritance have yet to be identified. Siblings of children with VUR have a 25-33% risk of also having VUR, whereas offspring of parents with reflux have a 66% incidence (higher in female offspring than male offspring). Even when asymptomatic, these siblings and offspring can have high-grade reflux and often have renal scarring at evaluation. [7]

Screening of asymptomatic siblings and offspring continues to be an area of controversy. Advocates point out that early identification of children with reflux may prevent episodes of UTI and renal scarring, but other authorities feel that screening asymptomatic individuals is likely to result in significant overtreatment of clinically insignificant VUR, with associated morbidity. As a middle ground, some pediatric urologists screen newborn siblings of children with VUR but do not screen their older, asymptomatic siblings.

Many large studies have been performed in Europe, where the prevalence of VUR is estimated to be similar to that in the United States. Disease frequency in other parts of the world is not well described but has been shown to be lower in people of West African descent.

VUR is more common among infants and progressively resolves in a substantial proportion of children; thus, prevalence decreases as children age. One study of patients who presented with UTI reported prevalence figures of 70% in patients younger than 1 year, 25% in patients aged 4 years, 15% in those aged 12 years, and 5.2% in adult patients. [5]

UTIs are more common in females, as one might expect from the anatomic differences. This leads to greater screening and, therefore, diagnosis of VUR in females. However, among all children with UTI, boys are more likely to have VUR than girls are (29% of males vs 14% of females). Boys also tend to have higher grades of VUR diagnosed at younger ages, but their reflux is more likely to resolve.

Reflux is more common in white children than in those of other races. This disparity extends to children with antenatal hydronephrosis. The editor of this article reviewed his antenatal registry of 1019 patients with antenatal hydronephrosis and found a 15% incidence of VUR in African American patients enrolled in the registry. Although VUR is less common in black children, screening is still recommended after a single UTI in this population. Because little is known about the specific genetic linkage of VUR and because of the wide variation of genes with intermarriage, excluding any group from evaluation is difficult.

Although VUR is much less common in other ethnic groups, the range of severity and rate of spontaneous resolution (grade for grade) are similar between the races.

With modern antibiotics and supportive care, mortality from acute pyelonephritis in children with VUR is very rare.

Studies comparing medical management with surgical treatment of primary VUR have demonstrated that both have excellent long-term outcomes if surveillance is conscientious and compliance is good. Rates of reflux nephropathy are similar in the two groups, though surgically treated patients have a lower prevalence of pyelonephritis. Studies of adults with childhood reflux and children presenting to a pediatric nephrology clinic have shown that the prevalence of reflux nephropathy in these groups is substantially lower than in historical series. Whether this phenomenon is a result of aggressive treatment of VUR, changes over time in definitions of reflux nephropathy, or other factors is not known.

Treatment of children with secondary reflux continues to pose challenges to pediatricians and urologists. A clear understanding of bladder function is essential. Other children have complex combinations of reflux, obstruction, and bladder and renal dysfunction that require a concerted multidisciplinary approach to achieve the maximum potential benefit of therapy.

Effective education of parents and effective communication with the primary care physician are essential if medical management is to be successful.

Poor compliance and untreated episodes of UTI are likely to lead to reflux nephropathy.

[Guideline] Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management., Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011 Sep. 128 (3):595-610. [Medline].

Weiss R, Duckett J, Spitzer A. Results of a randomized clinical trial of medical versus surgical management of infants and children with grades III and IV primary vesicoureteral reflux (United States). The International Reflux Study in Children. J Urol. 1992 Nov. 148 (5 Pt 2):1667-73. [Medline].

Walker RD. Vesicoureteral reflux and urinary tract infection in children. Gillenwater JY, Grayhack JT, eds. Adult and Pediatric Urology. 3rd ed. St Louis: Mosby-Year Book; 1996. 2259-96.

RIVUR Trial Investigators, Hoberman A, Greenfield SP, Mattoo TK, Keren R, Mathews R, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014 Jun 19. 370 (25):2367-76. [Medline]. [Full Text].

Smellie JM, Prescod NP, Shaw PJ, Risdon RA, Bryant TN. Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults. Pediatr Nephrol. 1998 Nov. 12 (9):727-36. [Medline].

Ransley PG, Risdon RA. Reflux nephropathy: effects of antimicrobial therapy on the evolution of the early pyelonephritic scar. Kidney Int. 1981 Dec. 20 (6):733-42. [Medline].

Hunziker M, Colhoun E, Puri P. Renal cortical abnormalities in siblings of index patients with vesicoureteral reflux. Pediatrics. 2014 Apr. 133 (4):e933-7. [Medline].

Nelson CP, Johnson EK, Logvinenko T, Chow JS. Ultrasound as a screening test for genitourinary anomalies in children with UTI. Pediatrics. 2014 Mar. 133 (3):e394-403. [Medline].

Broadis E, Kronfli R, Flett ME, Cascio S, O’Toole SJ. ‘Targeted top down’ approach for the investigation of UTI: A 10-year follow-up study in a cohort of 1000 children. J Pediatr Urol. 2016 Feb. 12 (1):39.e1-6. [Medline].

Lee YJ, Lee JH, Park YS. Risk factors for renal scar formation in infants with first episode of acute pyelonephritis: a prospective clinical study. J Urol. 2012 Mar. 187 (3):1032-6. [Medline].

Edmondson JD, Maizels M, Alpert SA, Kirsch AJ, Hanna MK, Weiser AC, et al. Multi-institutional experience with PIC cystography–incidence of occult vesicoureteral reflux in children with febrile urinary tract infections. Urology. 2006 Mar. 67 (3):608-11. [Medline].

Guidos PJ, Arlen AM, Leong T, Bonnett MA, Cooper CS. Impact of continuous low-dose antibiotic prophylaxis on growth in children with vesicoureteral reflux. J Pediatr Urol. 2018 Jul 23. [Medline].

Edmonson MB, Eickhoff JC. Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis. JAMA Pediatr. 2017 Feb 1. 171 (2):150-156. [Medline].

Routh JC, Inman BA, Reinberg Y. Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics. 2010 May. 125 (5):1010-9. [Medline].

Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R, et al. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol. 2006 Feb. 175 (2):716-22. [Medline].

Kocaoglu C. Endoscopic treatment of grades IV and V vesicoureteral reflux with two bulking substances: Dextranomer hyaluronic acid copolymer versus polyacrylate polyalcohol copolymer in children. J Pediatr Surg. 2016 Oct. 51 (10):1711-5. [Medline].

De Badiola FI, Soria R, Vagni RL, Ormaechea MN, Moldes JM, Benmaor C. Results of Treatment of Grades IV and V Vesicoureteral Reflux with Endoscopic Injection of Polyacrylate Polyalcohol Copolymer. Front Pediatr. 2013. 1:32. [Medline].

Warchoł S, Krzemień G, Szmigielska A, Bombiński P, Toth K, Dudek-Warchoł T. Endoscopic correction of vesicoureteral reflux in children using polyacrylate-polyalcohol copolymer (Vantris): 5-years of prospective follow-up. Cent European J Urol. 2017. 70 (3):314-319. [Medline].

Timberlake MD, Peters CA. Current status of robotic-assisted surgery for the treatment of vesicoureteral reflux in children. Curr Opin Urol. 2017 Jan. 27 (1):20-26. [Medline].

Boysen WR, Akhavan A, Ko J, Ellison JS, Lendvay TS, Huang J, et al. Prospective multicenter study on robot-assisted laparoscopic extravesical ureteral reimplantation (RALUR-EV): Outcomes and complications. J Pediatr Urol. 2018 Jun. 14 (3):262.e1-262.e6. [Medline].

Hubert KC, Kokorowski PJ, Huang L, Prasad MM, Rosoklija I, Retik AB, et al. New contralateral vesicoureteral reflux after unilateral ureteral reimplantation: predictive factors and clinical outcomes. J Urol. 2014 Feb. 191 (2):451-7. [Medline].

Arlen AM, Scherz HC, Filimon E, Leong T, Kirsch AJ. Is routine voiding cystourethrogram necessary following double hit for primary vesicoureteral reflux?. J Pediatr Urol. 2015 Feb. 11 (1):40.e1-5. [Medline].

Caleb P Nelson, MD, MPH Assistant Professor of Surgery (Urology), Department of Urology, Harvard Medical School; Consulting Staff, Department of Urology, Children’s Hospital Boston

Caleb P Nelson, MD, MPH is a member of the following medical societies: American Urological Association, Endourological Society, Phi Beta Kappa, Society for Pediatric Urology, Society for Fetal Urology

Disclosure: Nothing to disclose.

Harry P Koo, MD Chairman of Urology Division, Director of Pediatric Urology, Professor of Surgery, Virginia Commonwealth University School of Medicine, Medical College of Virginia; Director of Urology, Children’s Hospital of Richmond

Harry P Koo, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Urological Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Martin David Bomalaski, MD, FAAP Pediatric Urologist, Alaska Urology; Clinical Assistant Professor, Seattle Children’s Hospital

Martin David Bomalaski, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Urological Association

Disclosure: Nothing to disclose.

Marc Cendron, MD Associate Professor of Surgery, Harvard School of Medicine; Consulting Staff, Department of Urological Surgery, Children’s Hospital Boston

Marc Cendron, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, New Hampshire Medical Society, Society for Pediatric Urology, Society for Fetal Urology, Johns Hopkins Medical and Surgical Association, European Society for Paediatric Urology

Disclosure: Nothing to disclose.

Bartley G Cilento, Jr, MD Instructor, Department of Surgery, Division of Urology, Children’s Hospital of Boston and Harvard Medical School

Bartley G Cilento, Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, Massachusetts Medical Society

Disclosure: Nothing to disclose.

Pediatric Vesicoureteral Reflux

Research & References of Pediatric Vesicoureteral Reflux|A&C Accounting And Tax Services